



PHARMACY CONTINUING EDUCATION FROM WF PROFESSIONAL ASSOCIATES

PharmCon, Inc. • 341 Wellness Drive • Myrtle Beach, South Carolina 29579 • 843.488.5550 (Website)

www.ce-prn.com • (Email) info@ce-prn.com • (Fax) 843-488-5554

## “UPDATE: Hospital Acquired Infections”

February 2018



**ALWAYS CHECK YOUR CPE MONITOR ACCOUNT. TYPICALLY, CREDITS APPEAR IN THAT ACCOUNT WITHIN 7 DAYS AFTER WE RECEIVE QUIZ ANSWERS. ALL 2017 CREDITS SHOULD BE IN YOUR cpeMONITOR ACCOUNT.**

**WHEN YOU SEND IN QUIZ ANSWERS, ALWAYS KEEP A COPY. YOU MAY MAIL, EMAIL OR FAX THEM. FAX # IS 843-488-5554. OR SEND A CONVENTIONAL EMAIL WITH ANSWERS TO info@ce-prn.com.**

Infections that are facilitated within the hospital setting are becoming more prevalent. Additionally, the reaction to them by all members of the healthcare team are becoming more significant. Finally, third party payers are starting to 'scrutinize reimbursement' to hospitals for certain infections. These are just a few reasons why it is important to review and update this topic every 12 – 18 months. As always the overall goals are to provide safe and effective pharmacy care, while advising patients with reliable and important information.

This lesson provides 1.25 hours (0.125 CEUs) of credit, and is intended for pharmacists & technicians in all practice settings.

**The program ID # for this lesson is 0798-0000-18-219-H01-P for pharmacists, and 0798-0000-18-219-H01-T for technicians.**

**Participants completing this lesson by January 31, 2021 may receive full credit. Release date for this lesson is February 1, 2018.**

**To obtain continuing education credit for this lesson**, you must answer the questions on the quiz (70% correct required), and return the quiz. Should you score less than 70%, you will be asked to repeat the quiz. Computerized records are maintained for each participant.

If you have any comments, suggestions or questions, contact us at the above address, or call 1-843-488-5550. **Please write your name, NABP eProfile (CPE Monitor®) ID Number & birthdate (MM/DD) in the indicated space on the quiz page.**

**The objectives of this lesson are such that upon completion participants will be able to:**

**For Pharmacists:**

1. Relate the impact of nosocomial infections on the healthcare system.
2. Discuss the pathophysiology & microbiology of nosocomial infections.
3. List & describe preventive measures required to minimize (avoid) nosocomial infections.

**For Technicians:**

1. Define “nosocomial infections.”
2. Discuss causes & sources of nosocomial infections.
3. List & describe preventive measures required to minimize (avoid) nosocomial infections.

All opinions expressed by the author/author(s) are strictly their own and are not necessarily approved or endorsed by PharmCon, Inc.

Consult full prescribing information on any drugs or devices discussed.

CE-PRN is a division of PharmCon, Inc., 341 Wellness Drive, Myrtle Beach, South Carolina 29579.

CE-PRN is published eleven times per year, monthly, January through November.

## INTRODUCTION

Hospital-acquired Infections (HAIs) or nosocomial infections are infectious complications that patients acquire from a hospital stay. These can be devastating and even fatal. In a recent prevalence study, it was found that there were over 700,000 HAIs in United States acute care hospitals in 2011, with over 75,000 patients dying from these infections. The most common infections were pneumonia (22%) and surgical site infections (22%), but closely followed by gastrointestinal infections (17%), urinary tract infections (13%) and blood stream infections (10%). Over half of the HAIs occurred outside of the intensive care unit. The most common causes of these infections were *Clostridium difficile* (12%), methicillin-resistant *Staphylococcus aureus* (MRSA) (11%), *Klebsiella* (10%), *Escherichia coli* (9%), *Enterococcus* (9%), and *Pseudomonas* (7%).<sup>1</sup> The annual direct medical costs associated with HAIs range from 35 to 45 billion dollars.<sup>2</sup> The infections related to transmitted organisms in the hospital environment are considered to be preventable, and certain infections are no longer reimbursable by the Center for Medicare and Medicaid Services (CMS).

During the past decade, there has been increased awareness and efforts of understanding and preventing infections in the hospital environment. Transmission within a healthcare setting requires the interplay of three elements: (1) the source of the infectious agent, (2) the susceptible host with a portal entry receptive to the organisms and (3) a mode of transmission for the infectious agent. The Center for Disease Control and Prevention (CDC) and the Healthcare Infection Control Practices Advisory Committee (HICPAC) have published guidelines to promote the prevention of transmitting infectious agents in the healthcare setting to patients.<sup>3</sup> These guidelines are the standard of care for all institutions including hospitals, long-term facilities, ambulatory settings and home care. The hospital environment is filled with pathogenic organisms. These organisms can be found on the hands of healthcare providers, on doorknobs, keyboards, or even on medical equipment. The human reservoirs include patients, healthcare providers and household members and visitors. The source individuals may have an active infection, or may be colonized (either transiently or chronically) with pathogenic organisms. Infection with pathogenic organisms is a complex interplay between the host and the infectious agent. Some hosts are susceptible to symptomatic disease from exposure to pathogenic organisms, whereas some hosts remain asymptomatic. The immune status of the patient at the time of the exposure to an infectious agent, interaction between pathogen, and the virulence factors are important predictors of an individual's outcome. Underlying patient factors such as age, co-morbid conditions, immune status, malignancy and transplants can increase the susceptibility to infection. Medications that alter endogenous gastrointestinal flora (i.e. antimicrobial agents, gastric acid suppression, corticosteroids, immunosuppressive drugs, and chemotherapeutic agents) can also increase a patient's risk to develop an infection. The skin is also an important defense to prevent infections; surgical procedures and radiation therapy may impair this defense. Indwelling devices such as urinary catheters, endotracheal tubes, central venous and arterial catheters and synthetic implants allow the development of nosocomial infections by allowing the organisms to bypass the natural defenses. The foreign devices provide surfaces that facilitate the development of biofilms. Biofilms provide a surface that allow the adherence of microorganisms and often prevent antimicrobial activity. Infections associated with an invasive procedure or device is a result of either the patient's endogenous flora or transmission from within the healthcare facility.

## INFECTION PREVENTION IN THE HOSPITAL SETTING

The hospital environment plays a crucial role in exposing patients to various microorganisms. Because pathogens can be found on the hands of healthcare workers and in the hospital surroundings, multiple measures have been studied to reduce this burden and subsequently lower the rates of nosocomial infections.<sup>3</sup>

### HAND HYGIENE

Adherence to appropriate infection control practices decreases transmission of pathogens. One key measure of infection control is proper hand hygiene. It is an essential part of “Standard Precautions.” The details of Standard Precautions can be found in the CDC and Healthcare Infection Control Practices Advisory Committee (HICPAC) guidelines.<sup>3</sup> Hand hygiene includes both hand washing with soap, plain or antiseptic, and use of alcohol-based products that do not use water. Alcohol-based products used for hand disinfection are preferred over soap and water because of their superior microbial activity, reduced drying of the skin and convenience. It is important to note that certain organisms, like *C. difficile*, are resilient to the alcohol-based products. Hand washing with soap and water is recommended over alcohol-based products when taking care of patients with *C. difficile* infections.<sup>3</sup> Adherence to hand hygiene practices has been associated with decreased incidence of resistant organisms, including methicillin-resistant *S. aureus* (MRSA) and Vancomycin-Resistant *Enterococcus* (VRE).<sup>4</sup> In addition to hand hygiene, isolating patients that are colonized with resistant organisms and thorough environmental cleaning are essential to preventing avoidable transmission of nosocomial infections.

The Center for Medicare and Medicaid Services (CMS) will no longer reimburse additional payments for four HAIs which include: catheter-related bloodstream infections, Ventilator-associated pneumonia (VAP), surgical site infections (SSI) and catheter-associated urinary tract infections (CA-UTI). This has provided motivation for the healthcare administrators to provide additional resources for guidelines and preventive measures.

## VENTILATOR-ASSOCIATED PNEUMONIA (VAP) and HOSPITAL-ACQUIRED PNEUMONIA (HAP)

### Epidemiology

Together HAP and VAP contribute to 22% of all HAIs. It is estimated that VAP affects 52,000 patients per year in the United States with the mortality rate ranging from 20-50%.<sup>5,6</sup> VAP is associated with increased hospital stays of 7 to 9 days per patient and increases costs to over \$40,000 per patient.<sup>6</sup>

### Definition

HAP is defined as a pneumonia that is not present (or incubating) at the time of admission but develops greater than 48 hours after hospital admission. Ventilator-associated pneumonia (VAP) is a pneumonia that occurs in a patient who is mechanically ventilated for more than 48 hours. Definitions of VAP vary amongst organizations. The CDC and NHSN (National Healthcare Safety Network) definitions are complex, but they tend to follow clinical guidelines. In general, the signs and symptoms for VAP include: fever, chills, malaise, purulent respiratory secretions, rhonchi, leukocytosis, an infiltrate on a chest X-ray and impaired oxygenation and ventilation. Blood cultures may be positive but have a low sensitivity (25%) because the organisms may originate from another source. The microbiologic diagnosis of VAP is made from a respiratory tract culture obtained from the upper or lower airways. A sterile culture from a lower tract (i.e.

invasive testing such as bronchoscopy, bronchoalveolar lavage or protected brush specimen sample) is often preferred because tracheal colonization can contaminate upper airway cultures, but 2016 Infectious Diseases Society of America (IDSA) guidelines do not recommend invasive testing over endotracheal aspiration (i.e. sputum cultures).<sup>5,6</sup>

### **Pathogenesis, Microbiology and Treatment**

The majority of HAP and VAP cases are caused by aerobic gram-negative bacilli, specifically *Acinetobacter* species, *Pseudomonas aeruginosa*, *E. coli*, *Klebsiella* species and others. The remaining cause of VAP is *Staphylococcus aureus* including MRSA. Empiric treatment is guided by local antimicrobial susceptibility patterns and risk factors for multi-drug resistant organisms. Risk factors for MDR (multiple drug resistant) organisms include antimicrobial therapy in preceding 90 days, current hospitalization of 5 days or more, high frequency of antibiotic resistance in the community or specific hospital location, or immunosuppressive disease and/or therapy. A regimen recommended by the American Thoracic Society (ATS) guidelines includes an anti-pseudomonal antibiotic (e.g. ceftazidime, cefepime, ciprofloxacin, piperacillin-tazobactam, meropenem or imipenem) in combination with an antibiotic effective against MRSA (e.g. linezolid or vancomycin).<sup>6</sup> Once definitive cultures return, antibiotic therapy should be tailored to the narrowest possible spectrum. In addition, if the quantitative cultures are below diagnostic threshold for HAP or VAP, then the antibiotics should be stopped. The optimal antibiotic duration of HAP and VAP in adult patients is 7 days, but this can be shortened or prolonged based on the patient's clinical response.

### **Prevention**

The pathogenesis of VAP is a fine balance between host defenses and microbial colonization and invasion.<sup>5,6</sup> The microorganisms must persist and invade the lower respiratory tract in order to cause VAP. Healthcare devices or the environment including air, water and other fomites can serve as the source of the infections. The transfer of microorganisms between staff and patients can also serve as a source for infections. The entry of microorganisms into the lower respiratory tract can occur when a patient aspirates oropharyngeal pathogens or bacteria around the endotracheal cuff and they leak into the trachea.<sup>6</sup>

Preventative measures are targeted towards the pathogenesis of VAP. First and foremost, intubation and mechanical ventilation should be avoided whenever possible, and non-invasive ventilation should be used when clinically appropriate.<sup>6,7</sup> If patients are intubated, the duration of ventilation should be minimized. Assessments for readiness to wean ventilation should be performed daily. Many institutions have weaning protocols and guidelines that focus on minimizing sedation administration. These measures shorten exposure to the endotracheal tube and aspiration of contaminated secretions. Maintaining patients in a semi-recumbent position (30-45° elevation of the head of the bed) reduces the risk of aspiration. In a multivariate analysis for risk factors for VAP, patients who maintained semirecumbency during the first 24 hours of mechanical ventilation reduced their risk for VAP by 67%.<sup>7</sup>

The progression of the oropharyngeal colonization to tracheobronchitis to pneumonia is a dynamic process. Oropharyngeal colonization is an independent risk factor for the development of VAP. Several strategies have been tested to reduce colonization such as the administration of prophylactic antibiotics, routine use of oral chlorhexidine, gastric acid suppression for stress ulcer prophylaxis, and selective decontamination of the digestive tract. Acid suppressive therapy may increase colonization with potential pathogenic organisms. Several randomized trials

have provided controversial results on the benefits of routine stress ulcer prophylaxis with either sucralfate or H2-antagonists to prevent VAP.<sup>6,7</sup> The American Thoracic Society recommends either sucralfate or H2-antagonists for those patients at risk for stress bleeding. Routine oral care with chlorhexidine mouth wash reduces the oropharyngeal colonization, therefore, is recommended by the Infectious Disease Society of America.<sup>6</sup> Routine systemic antibiotics and selective decontamination of the digestive tract strategies to prevent VAP are not recommended by the Infectious Disease Society of America (IDSA) or ATS guidelines. Lastly, the CDC recommends infection control strategies that include proper hand-hygiene to eliminate contamination from healthcare workers to patients. Institutions are recommended to monitor adherence to these national guidelines in order to minimize the incidence of VAP.

## CATHETER-ASSOCIATED URINARY TRACT INFECTIONS

### Epidemiology

Urinary tract infections (UTIs) are a common nosocomial infection. They are estimated to cause 440,000 infections each year in the United States.<sup>5</sup> A majority of the UTIs are caused by instrumentation, namely catheterization, of the urinary tract. Catheter-Associated Urinary Tract Infections (CA-UTIs) are associated with increased morbidity, mortality and costs.<sup>8,9</sup> Attributed costs associated with CA-UTIs add \$800 per patient case, and overall contribute nationally to \$450 million in hospital costs in the United States.<sup>5</sup>

### Definition

An indwelling catheter is a drainage tube that is inserted into the urinary bladder through the urethra which is connected to a closed collection system.<sup>9</sup> This is also known as a Foley catheter. Alternative methods can be employed such as intermittent catheters, or external catheters or a surgically inserted suprapubic catheter. CA-UTIs that are reported to the National Healthcare Safety Network (NHSN) only refer to infections related to indwelling catheters. UTIs can be classified into 3 categories: symptomatic, asymptomatic and others. Asymptomatic bacteriuria (ASB) is a condition in which a patient with or without an indwelling catheter has no signs or symptoms of infection (i.e. no fever, urinary urgency, dysuria, suprapubic tenderness or costovertebral angle pain), but they do have a positive urinary culture with no more than two uropathogens. Uropathogens include gram-negative bacilli, *Staphylococcus* spp, yeasts, beta-hemolytic *Streptococcus* spp, *Enterococcus* spp, *G.vaginalis*, *Aerococcus urinae* and *Corynebacterium* (urease positive).<sup>8,9,10</sup> Treatment of ASB has not shown to be beneficial and contributes to the presence of antimicrobial-resistant organisms and *C.difficile* infections.<sup>9</sup> Often ASB can be treated with removing the indwelling catheter without use of systemic antibiotics.

CA-UTI is defined by the CDC as a patient with an indwelling urinary catheter at the time of specimen collection and at least one sign or symptom without another recognized cause (fever, suprapubic tenderness, or costovertebral angle pain or tenderness and a positive urine culture ( $>10^5$  colony-forming units/ml) with no more than 2 species of microorganisms.<sup>9,10,11</sup> A patient can have a CA-UTI after the Foley catheter has been removed; therefore, the CDC provides an alternate definition for those patients. Patients who had a Foley catheter removed within 48 hours prior to specimen collection and at least one of the following signs or symptoms without another recognized cause (fever, urgency, frequency, dysuria, suprapubic tenderness, or costovertebral angle pain or tenderness and a positive urine culture ( $>10^5$  colony-forming units/ml) with no more than 2 species of microorganisms).

### Pathogenesis, Microbiology and Treatment

CA-UTIs are caused by microorganisms found in the meatal, rectal or vaginal areas.<sup>9,10</sup>

They can also be caused by an exogenous source such as contaminated hands of healthcare providers or equipment. The bacteria can enter the urinary tract either by an extraluminal route by migrating along the outside of the catheter. The bacteria can also move along the internal lumen of the catheter from the contaminated collection bag. The pathogens that most frequently cause CA-UTIs include *E.coli*, *Candida* spp, *Enterococcus* spp, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae* and *Enterobacter* spp. The bacteria can form a biofilm (matrix of sessile microorganisms and host proteins) on the surface of the catheter and drainage system which universally occurs with prolonged duration of catheterization. The bacterial biofilm is resistant to antimicrobials and host defenses; they are impossible to eradicate unless the catheter is removed.<sup>9</sup> Therefore, the mainstay of treatment for CA-UTIs is catheter removal and appropriate targeted antimicrobial therapy.<sup>5</sup> Antimicrobial irrigation is not recommended.

### **Prevention**

The key to preventing CA-UTI is judicious use of an indwelling catheter. It is estimated that 1 in 5 hospitalized patients have a catheter placed.<sup>5</sup> Indwelling catheters should only be used for select indications, such as: patients with acute urinary retention or bladder outlet obstruction, critically ill patients who require assessment of urinary output, patients who had selected surgical procedure (e.g. urology procedures, prolonged duration of surgery, etc), patients who require assistance with healing of open sacral or perineal wounds in incontinent patients, or patients who require prolonged immobilization.<sup>11</sup> The CDC guidelines emphasize that indwelling catheters should not be used as a substitute for nursing care, as a means of obtaining urine for culture or other diagnostic tests when a patient can voluntarily void, or for prolonged postoperative duration without appropriate duration. Patients with an indication for an indwelling catheter should have it removed as soon as possible, preferably within 24 hours if clinically appropriate. In addition, educational guidelines should emphasize sterile insertion technique, maintenance practices that keep the collection bag below the bladder to avoid reflux and preventing breaks in the collection system. A recent study conducted at the Minneapolis VA facility demonstrated that a multi-faceted approach including education, system redesign, rewards and feedback and involvement of a dedicated Foley catheter nurse significantly reduced inappropriate Foley catheter infection.<sup>10</sup> System-wide strategies to reduce CA-UTI have been recently reviewed by the Society of Healthcare Epidemiology and IDSA.<sup>11</sup> Strategies include development of guidelines for catheter use, insertion and maintenance, ensuring that only trained personnel insert urinary catheters and performing surveillance for CA-UTI.

## **SURGICAL SITE INFECTION**

### **Epidemiology**

Surgical site infections (SSIs) contribute to 17% of all HAIs, second to CA-UTIs. It is estimated that SSIs occur in 2-5% of patients undergoing inpatient clean (extra-abdominal) surgeries and up to 20% of patients undergoing abdominal surgeries.<sup>12,13</sup> Patients with SSIs have increased morbidity and mortality; they have up to 11 times higher risk of death. Surgical site infections cost an additional \$3,000 to \$29,000 per case depending on the procedure and pathogen. The costs attributed to SSIs are up to \$10 billion annually in the United States.<sup>5,13</sup>

### **Definition**

Surgical site infections are classified by the infected site; they are superficial incisional (involving the skin or subcutaneous tissue), deep incisional (involving the fascia and/or muscular layers), or organ space. Surgical site infections often have positive bacterial cultures from the infected site (i.e. tissue or fluid) and often have purulent drainage. In general, the majority of SSIs

are found within 48 hours of the surgical procedure.<sup>12,13</sup>

### **Pathogenesis, Microbiology and Treatment**

Many SSIs are a result of the invasion of microorganisms into the surgical site at the time of the operation. The pathogens may come from the patient's own flora, seeding from a distant focus of infection, or other exogenous sources, such as surgical personnel, the operating room environment and ventilation or surgical tools and equipment.<sup>5,12</sup> The risk for SSI is a complex interplay between the microbe, patient, and surgical characteristics. Certain individual characteristics place patients at a higher risk for postoperative infections, such as advanced age, presence of diabetes mellitus, smoking status, nutritional status, body mass index, immunosuppression, and other co-morbid conditions (renal and hepatic failure). In addition, the characteristics of the surgery (i.e. the type of surgery, introduction of foreign material and amount of tissue damage) can affect the risk for SSIs.<sup>12</sup>

*Staphylococcus aureus* remains the most common microorganism isolated from SSIs from clean procedures. Other endogenous organisms may be involved in SSIs that may be present at the surgical site or resected organ (i.e. gastrointestinal, gynecological, respiratory tract).<sup>5,14</sup>

### **Treatment**

The mainstay for treatment is drainage of the infected wound, supplemented by wound care.<sup>5</sup> Systemic antimicrobial therapy should be administered and should be targeted to the isolated organism. Wound sponges with suction (vacuum-assisted closure (VAC)) have been used to assist with wound closure and maintenance.

### **Prevention**

Many preventive measures have been reported to reduce the rate of complications associated with SSI.<sup>5,12</sup> Many organizations (CMS and Surgical Infection Prevention Collaborative) joined together to improve adherence to the best practices for avoiding SSIs. Three performance measures for quality improvement strategies related to antimicrobial therapy have been instituted: delivery of intravenous antimicrobial prophylaxis within 1 hour before incision (2 hours before incision for Vancomycin and fluoroquinolones); the use of antimicrobial prophylactic agents consistent with published guidelines; and discontinuation of the use of the prophylactic agents after the incision is closed.<sup>13</sup> However, some guidelines still suggest that antibiotics may be continued up to 24 hours after the surgery. The timing of antimicrobial administration is based on maximizing the bactericidal concentrations at the time of the incision. The Surgical Infection Society and the American Society of Health System Pharmacists (ASHP) published guidelines which detail the appropriate dosing and selection for specific procedures.<sup>14,15</sup> In addition to these pharmacological interventions, the Surgical Infection Prevention Collaborative recommended three additional process measures to prevent SSIs. These include: proper hair removal (avoid razors for hair removal); controlling blood glucose level during immediate postoperative period; and maintenance of perioperative normothermia.<sup>5,13,14</sup>

## **CATHETER-RELATED BLOODSTREAM INFECTION**

### **Epidemiology**

Intravenous catheter use in the nosocomial setting is common. It is estimated that central venous catheter use exceeds 15 million catheter-days each year in the United States.<sup>5</sup> Central line-associated bloodstream infections (CLABSI) are the majority of the infections in this group, with approximately 92,000 cases per year. The costs related to CLABSI are estimated to be \$25,000 to \$45,000 per case. As with other nosocomial infections, CLABSI are associated with

increased length of hospital stay and costs, but they have not been associated with increased mortality.<sup>5,15,16</sup>

### Definitions

CLABSIs are defined when microbiologic and clinical symptoms suggest the catheter as the source of the infection. Some signs and symptoms of CLABSIs include: both local (e.g. erythema, induration, purulence and tenderness at catheter site) and systemic signs of infection (e.g. fever and leukocytosis). Some patients may only have the systemic signs and symptoms. Central-line associated bloodstream infections may be considered in a patient who has had surgery within 48 hours prior to the development of the blood stream infection, and it is unrelated to another source of infection.<sup>5,15</sup>

### Pathogenesis, Microbiology and Treatment

CLABSIs are caused by translocation of skin flora along the surface of the catheter. Bacteria can also be introduced by direct contamination of the catheter or catheter hub by contact with hands or contaminated fluids or devices.<sup>16</sup> Less often, the catheters may become hematogenously seeded from another focus of infection or rarely contaminated infusate might lead to CLABSI. Often the bacteria develop a biofilm which may be impermeable to antibiotics and evades the immune system. The most common causative microorganisms remain to be coagulase-negative *Staphylococci*, *Staphylococcus aureus*, *Enterococci* and *Candida* spp. Gram-negative organisms also cause CLABSI. As with other nosocomial infections, antimicrobial resistance is a continued problem limiting treatment options.<sup>16</sup>

The mainstay of CLABSI treatment is the removal of the catheter, except for those caused by coagulase-negative *Staphylococcus*. CLABSI caused by fungi, *S.aureus* or gram-negative bacilli should be treated with systemic antimicrobials and removal of the catheter. Antibiotic therapy should be narrowed to the isolated organism. The duration of therapy can range from seven to ten days, up to 4-8 weeks, if there is a complicated infection (i.e. infected thrombus, endocarditis, or osteomyelitis).<sup>5</sup>

### Prevention

CLABSI can be reduced by improving education and training, appropriate staffing and the use of process checklists. The appropriate site selection (i.e. avoiding the femoral site), hand hygiene, aseptic technique and use of antiseptic skin preparations are essential. In addition, careful and appropriate catheter site care is essential to avoid CLABSI.<sup>18</sup>

## **C.difficile INFECTION (CDI)**

The reported incidence of *C. difficile* infection has risen dramatically since the 1990s.<sup>18,19,20</sup> In the mid 1990s, the reported incidence of CDI in acute care hospitals in the United States was 30 to 40 cases per 100,000 population, rose to almost 50 cases per 100,000 in 2001, and up to 84 cases per 100,000 in 2005. In 2011, it was estimated that *C.difficile* caused half a million infections with only 24% of the cases occurring in the acute care setting. In addition, an estimated 83,000 patients had at least one recurrence, and 29,000 died within 30 days of diagnosis.<sup>21</sup> Also, to the rise of endemic CDI, there have been multiple outbreaks in many medical centers, both nationally and internationally. Not only is the increase in the number of outbreaks concerning, but the disease severity and mortality are alarming as well.

### Definition

*Clostridium difficile* is a spore-forming, obligate-anaerobic, gram-positive rod bacterium. It earned the name "difficile" because of the difficulty with which microbiologists originally

cultivated this species.<sup>21</sup> This organism is usually a harmless commensal of the GI flora.

Some patients who harbor toxigenic strains of *C. difficile* in their GI tract will develop clinical illness, usually when they are treated with antimicrobials for other conditions. This illness may occur anywhere on a spectrum that spans from mild-moderate disease (watery diarrhea with or without abdominal pain or cramping) to severe disease (significant leukocytosis, hypovolemia, or fever), to severe disease with complications (toxic megacolon-induced ileus, intestinal perforation, bacteremia, or sepsis).

### **Pathogenesis, Microbiology and Treatment**

Antimicrobial therapy plays an integral role in the pathogenesis of CDI by altering the normal flora of the colon and allowing toxigenic *C. difficile* to flourish. Almost all antimicrobials have been associated with CDI, but the drugs most commonly implicated include clindamycin, third-generation cephalosporins, penicillins, TMP/SMX, and fluoroquinolones. As little as one dose of an antibiotic can increase the risk of CDI, and this increased risk may continue for up to eight weeks after discontinuing the drug.<sup>22</sup>

Another risk factor is exposure to settings where the organism is present, such as hospital environment or long-term care settings. Due to spore-forming capabilities, it is resistant to commonly used disinfectants, such as alcohol. Hand washing with soap and water is the preferred method of prevention in the healthcare setting, but should be supplemented with environmental cleaning with disinfectants with known activity against *C. difficile*. Evidence suggests that antimicrobial stewardship programs that alter prescribing patterns of antimicrobials in a hospital setting can reduce the incidence of CDI.<sup>22</sup>

Because stomach acidity serves as an important defense against the acquisition of enteric pathogens, it has been hypothesized that acid blockade with Proton pump Inhibitors (PPIs) might increase risk of CDI acquisition. The accumulation of observational data associating the risk of PPI use and CDI lead to an FDA warning in August 2012. The FDA warning states that there may be an association between CDI, and a diagnosis of CDI should be considered for patients taking PPIs who develop diarrhea that does not improve.<sup>23</sup> In addition to PPIs increasing the risk of the first episode of CDI, a recently published meta-analysis suggests that patients taking acid suppressants (PPIs, histamine-2-receptor antagonists or both) were at higher risk of recurrent CDI.<sup>24</sup>

Diagnosing CDI in a timely fashion is necessary for the overall management of nosocomial CDI. The laboratory tests for *C. difficile* either evaluate the presence of the toxin or the presence of the organism.<sup>24,25</sup> The optimal strategy to provide the most timely, cost-effective and accurate diagnosis is still controversial. Treatment is necessary for all patients with clinical disease and whose fecal analysis confirms presence of *C. difficile*. The Infectious Disease Society of America (IDSA) has treatment guidelines that include oral metronidazole for mild to moderate disease, whereas vancomycin is recommended for severe disease, as indicated by high white blood cell count (> 15,000 cell/mm<sup>3</sup>) or elevated Serum creatinine.<sup>25</sup> The treatment duration is 10 to 14 days. Fidaxomicin is a new macrocyclic antibiotic with activity against *C. difficile* which has been FDA-approved for use in patients with CDI.<sup>26</sup> Fidaxomicin is significantly more expensive than oral vancomycin or metronidazole, so this may be a limitation for some patients. The IDSA guidelines were published prior to the approval of fidaxomicin, so they do not address the use of this agent in clinical practice, but it is likely to be recommended in upcoming guidelines. Patients with severe disease with complications, such as hypotension, shock, toxic megacolon, or ileus may require more aggressive treatment with a combination of intravenous metronidazole

and oral vancomycin and/or rectal vancomycin. In addition to the treatment directed toward *C.difficile*, it is imperative to discontinue the inciting antibiotic, when clinically appropriate.

## Prevention

Preventive strategies focus on the reduction of the overuse of antimicrobials and efforts to prevent transmission from patient to patient. Since exposure to antibiotics is the primary risk factor, antibiotics should be avoided unless absolutely necessary.<sup>25</sup> If antibiotics are prescribed, the narrowest spectrum should be selected with the shortest duration possible. To prevent transmission, proper hand washing and environmental cleaning are necessary. To minimize the spread of CDI, it is essential that these measures be promptly implemented when the diagnosis is suspected, rather than waiting for its confirmation.

## SUMMARY

Nosocomial infections are common and are a tremendous burden to patients and the healthcare system. The social, economic and personal costs related to nosocomial infections are overwhelming for many institutions but many researchers have demonstrated various interventions that decrease infection rates. A multi-faceted approach that includes staff education, minimizing patient risk factors and easy to understand institutional guidelines are needed to prevent nosocomial infections. This is an active area of research with advancements to patient care published frequently.

## ADDITIONAL RESOURCES:

- Center for Disease Control and Prevention: [www.cdc.gov/hai/](http://www.cdc.gov/hai/)
- Infectious Disease Society of America: [www.idsociety.org](http://www.idsociety.org)
- National Healthcare Safety Network (NHSN): [www.cdc.gov/nhsn](http://www.cdc.gov/nhsn).

## REFERENCES

1. Magill SS1, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. N Engl J Med 2014; 370:1198-1208
2. Scott DR. Division of Healthcare Quality Promotion National Center for Preparedness, Detection, and Control of Infectious Diseases Coordinating Center for Infectious Diseases. Center for Disease Control and Prevention. March 2009
3. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings
4. Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide program to improve compliance with hand hygiene. Infection Control Program. Lancet 2000;356(9238):1307-1
5. Lodbell KW, Stamou S, Sanchez JA. Hospital-Acquired Infections. Surg Clin N Am 2012; 92:65-77.
6. American Thoracic Society and the Infectious Diseases Society of America. Management of Adults with Hospital-acquired, Ventilator-associated Pneumonia. Clin Infect Dis 2016;63(5): e61–e111.
7. Coffin SE, Klompas M, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, Calfee DP, Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Lo E, Marschall J, Mermel LA, Nicolle L, Pegues DA, Perl TM, Sain S, Salgado CD, Weinstein RA, Wise R, Yokue DS. Infect Control Hosp Epidemiol 2008; 29:S31–S40.
8. Center for Disease Control and Prevention. Hospital-acquired Infections. <http://www.cdc.gov/nhsn/PDFs/slides/CAUTI.pdf> Accessed April 21st, 2012.
9. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA, and the Healthcare Infection Control Practices Advisory Committee (HICPAC) Guideline for Prevention Of Catheter-Associated Urinary Tract Infections 2009. [www.cdc.gov/hicpac/cauti/001\\_cauti.html](http://www.cdc.gov/hicpac/cauti/001_cauti.html). Accessed April 21st, 2012.

10. Knoll BM, Wright D, Ellingson L, Kraemer L, Patire R, Kuskowski MA, Johnson JR. Reduction of inappropriate urinary catheter use at a Veterans Affairs hospital through a multifaceted quality improvement project. *Clin Infect Dis*. 2011 Jun;52(11):1283-90
11. Lo E, Nicolle LE, Coffin SE, Gould C, Maragakis LL, Meddings J, Pegues DA, Pettis AM, Saint S, Yokoe DS Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol*. 2014 May;35(5):464-79.
12. Anderson DJ, Kaye KS, Classen D, Arias KM, Podgorny .K, Burstin H, Calfee DP, Coffin SE, Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Klompas M, Lo E, Marchall J, Mermel LA, Nicolle L, Pegues DA, Perl TM, Sanjay S, Salgado CD, Weinstein RA, Wise R, Yokoe DS. Strategies to prevent surgical site infections in acute care hospitals. *Infect Control Hosp Epidemiol* 2008;29:S51-S61
13. Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. *JAMA Surg*.2017;152(8):784-791
14. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm*. 2013 Feb 1;70(3):195-283
15. Center for Disease Control and Prevention. CDC/NHSN Surveillance Definitions for Specific Types of Infections. [https://www.cdc.gov/nhsn/PDFs/pscManual/4PSC\\_CLABScurrent.pdf](https://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf) Accessed October 29th, 2017.
16. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SKNHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. *Infect Control Hosp. Epidemiol* 2008;29:996-1011.
17. O'Grady, NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H , Mermel LA, Pearson ML, Raad II,Randolph A, Rupp ME, Saint S and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the Prevention of Intravascular Catheter-Related Infections. CDC. 2011 <http://www.cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf>
18. George RH, Symonds JM, Dimock F, et al. Identification of *Clostridium difficile* as a cause of pseudomembranous colitis. *Br Med J* 1978;1:695.
19. Bartlett JG, Moon N, Chang TW, et al. Role of *Clostridium difficile* in antibiotic-associated pseudomembranous colitis. *Gastroenterology* 1978;75(5):778-782.
20. Kelly CP, LaMont T. *Clostridium difficile* – More difficult than ever. *N Engl J Med* 2008,359: 1932
21. Lessa FC, Mu Y, Bamberg WM et al. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med* 2015; 372: 825-34..
22. Fekety R. Guidelines for the diagnosis and management of *Clostridium difficile*-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 1997;92(5):739-750.
23. (FDA) FDA. <https://www.fda.gov/Drugs/DrugSafety/ucm290510.htm>.
24. Tariq R, Singh S, Gupta A et al. Association of Gastric Acid Suppression With Recurrent *Clostridium difficile* Infection: A Systematic Review and Meta-analysis. *JAMA Intern Med* 2017.
25. Cohen SH, Gerding DN, Johnson S, et al.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;31 (5):431-455.
26. Louie TJ, Miller MA, Mullane KM, et al.;OPT-80-003 Clinical Study Group. Fidaxomicin versus Vancomycin for *Clostridium difficile* infection. *N Engl J Med* 2011;364(5):422-431.

CE-PRN

341 Wellness Dr Myrtle  
Beach, SC 29579

(Fax) 843-488-5554  
(Email) info@ce-prn.com

**WHEN YOU SEND IN QUIZZES, ALWAYS KEEP A COPY. YOU MAY MAIL OR FAX THEM.  
FAX # IS 843-488-5550 OR SEND A CONVENTIONAL EMAIL WITH  
YOUR ANSWERS TO [INFO@CE-PRN.COM](mailto:INFO@CE-PRN.COM).**

**ALL PHARMACISTS OR TECHNICIANS—READ THIS!!!**

**Check your CE activity or print a statement from your cpe Monitor® eProfile Account. To login, go to [www.nabp.net](http://www.nabp.net). Enter your user name (your email address) & your password. Click on "CE Activity" to view your history & print a CE report.**

**Contributing Faculty/Authors**

Rupali Jain, PharmD, FIDSA  
Clinical Associate Professor  
University of Washington  
School of Pharmacy

**Executive Editor**

William J. Feinberg, RPh, MBA



**CE-PRN** is a publication of PharmCon, Inc. PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Providers who are accredited by ACPE are recognized by **All** States for fulfilling CE requirements.

This is knowledge-based CPE.

Participants completing this lesson by January 31, 2021 may receive full credit.

Release date: February 1, 2018.

This lesson furnishes 1.25 (0.125 CEUs) contact hours of credit.

**Program ID # s for this lesson:**

**0798-0000-18-219-H01-P (for Pharmacists).**

**0798-0000-18-219-H01-T (for Technicians).**

CE Provider Registered # with CE Broker com is 50-3515.

**TO DOWNLOAD LESSONS FROM OUR WEBSITE!!!**

- Go to website [www.ce-prn.com](http://www.ce-prn.com)
- Click on "COURSES."
- Click on "YEAR."
- Click on the ID #"0798-0000-....." for your lesson of interest.

**FLORIDA PARTICIPANTS—READ THIS!** We don't know if you're Florida licensed unless you tell us.

Place your Florida license # on EVERY quiz.

Feb 2018 "Update: Hospital Acquired Infections (HAIs)" Volume 40 #2

Fill in the information below, answer questions and return **Quiz Only** for certification of participation to: CE-PRN , 341 Wellness Drive, Myrtle Beach, SC 29579.

**WHEN YOU SEND IN QUIZZES, ALWAYS KEEP A COPY. YOU MAY MAIL, EMAIL OR FAX THEM. FAX # IS 843-488-5554. OR SEND A CONVENTIONAL EMAIL WITH YOUR ANSWERS TO INFO@CE-PRN.COM**

NAME \_\_\_\_\_ CE PRN I.D.#(if you have it) \_\_\_\_\_

ADDRESS \_\_\_\_\_ CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_

I am a Pharmacist

I am a Technician

CPEMonitor ID \_\_\_\_\_ Birthdate (MM/DD) \_\_\_\_\_

ARE YOU LICENSED IN FLORIDA? IF YES, FL LIC # \_\_\_\_\_

EMAIL Address (REQUIRED) \_\_\_\_\_

**LESSON EVALUATION**

Please fill out this section as a means of evaluating this lesson. The information will aid us in improving future efforts. Either circle the appropriate evaluation answer, or rate the item from 1 to 7 (1 is the lowest rating; 7 is the highest).

- Does the program meet the learning objectives?  
Relate the impact of nosocomial infections on the healthcare system YES NO  
Discuss the pathophysiology & microbiology of nosocomial infections YES NO  
List & discuss preventive measures to avoid nosocomial infections YES NO
- Was the program independent & non-commercial? YES NO
- Relevance of topic  
Low Relevance 1 2 3 4 5 6 7 Very Relevant
- What did you like most about this lesson? \_\_\_\_\_
- What did you like least about this lesson? \_\_\_\_\_

**February, 2018. Vol 40 #2. "Update: Hospital Acquired Infections (HAIs)"**

**Please Mark the Correct Answer(s)**

- Healthcare associated infections are considered preventable and considered medical errors?**  
A. True  
B. False
- Healthcare associated infections are associated with increased healthcare expenditures in the U.S.**  
A. True  
B. False
- Transmission of Healthcare-acquired colonization or infection can occur via the following pathway(s):**  
A. A susceptible host with an indwelling device.  
B. A healthcare provider with colonization with an infections agent.  
C. An environment with an infectious agent.  
D. All of these
- Surgical site infections can be prevented by:**  
A. Delivery of antimicrobial prophylaxis within 1 hour before surgical incision.  
B. The use of appropriate antibiotic recommended by national guidelines.  
C. Discontinuation of prophylactic antibiotics within 48 hours of the procedure.  
D. A and B
- What are the key principles of Infection Control?**  
A. Hand hygiene.  
B. Environmental cleaning.  
C. Isolating patients colonized with resistant organisms.  
D. All of these.
- Ventilator associated pneumonia can be prevented by which method(s)?**  
A. Minimizing days on ventilator.  
B. Maintaining a prone position during ventilation.  
C. Routine systemic antibiotics.  
D. Bowel decontamination.
- Treatment of asymptomatic bacteriuria is associated with:**  
A. Selection of resistant bacteria.  
B. Improved cost.  
C. Reduced costs.  
D. All of these.
- Pathogenic organisms can be found in healthcare facilities on:**  
A. Healthcare providers.  
B. Doorknobs, keyboards, medical equipment.  
C. Patients.  
D. All of these.
- What are the preventive strategies for C. difficile infections?**  
A. Using antimicrobial wisely.  
B. Appropriate hand hygiene.  
C. Environmental cleaning.  
D. All of these.
- Catheter-related bloodstream infections are defined as:**  
A. Clinical symptoms suggestive of infection.  
B. Local symptoms related to the catheter.  
C. Symptoms arise within 24 hours of placement.  
D. A and C.